Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories. It also provides Cochlear true wireless devices comprising mini microphones, phone clips, and TV streamers; and Cochlear Vistafix bone-anchored facial prosthetic solutions to enhance the attachment and cosmetic outcome of facial prostheses. The company has strategic collaborations with Sensorion and GN Hearing A/S to focus on improving hearing outcomes in patients with cochlear implants. Cochlear Limited was incorporated in 1983 and is headquartered in Sydney, Australia.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 2 9428 6555
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3,500
Next Earnings DateN/A
OptionableNot Optionable
COCHLEAR LTD/ADR (OTCMKTS:CHEOY) Frequently Asked Questions
What is COCHLEAR LTD/ADR's stock symbol?
COCHLEAR LTD/ADR trades on the OTCMKTS under the ticker symbol "CHEOY."
What is the consensus analysts' recommendation for COCHLEAR LTD/ADR?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COCHLEAR LTD/ADR in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for COCHLEAR LTD/ADR.
Has COCHLEAR LTD/ADR been receiving favorable news coverage?
Headlines about CHEOY stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. COCHLEAR LTD/ADR earned a news impact score of -1.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for COCHLEAR LTD/ADR.
Who are some of COCHLEAR LTD/ADR's key competitors?
Some companies that are related to COCHLEAR LTD/ADR include Cannabix Technologies (BLO), Electromed (ELMD), Ellex Medical Lasers (ELXMF), GN Store Nord A/S (GGNDF), Neuroone Medical Technologies (NMTC), Ortho Regenerative Technologies (ORTH), PetVivo (PETV), Rafina Innovations (VICA), Sartorius Stedim Biotech (DIM), Sunniva (SNN), TELA Bio (TELA), Viemed Healthcare (VMD) and Vycor Medical (VYCO).
What other stocks do shareholders of COCHLEAR LTD/ADR own?
Who are COCHLEAR LTD/ADR's key executives?
COCHLEAR LTD/ADR's management team includes the folowing people:
- Mr. Diggory William Howitt, CEO, MD, Pres & Exec. Director (Age 52)
- Mr. Brent Andrew Cubis, Chief Financial Officer
- Mr. Jan Janssen, Chief Technology Officer
- Mr. Richard Brook, Pres of EMEA & Latin American Region
- Mr. Anthony Manna, Pres of Americas Region
How do I buy shares of COCHLEAR LTD/ADR?
Shares of CHEOY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is COCHLEAR LTD/ADR's stock price today?
One share of CHEOY stock can currently be purchased for approximately $75.52.
What is COCHLEAR LTD/ADR's official website?
How can I contact COCHLEAR LTD/ADR?
The company can be reached via phone at 61 2 9428 6555.
MarketBeat Community Rating for COCHLEAR LTD/ADR (OTCMKTS CHEOY)
MarketBeat's community ratings are surveys of what our community members think about COCHLEAR LTD/ADR and other stocks. Vote "Outperform" if you believe CHEOY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHEOY will underperform the S&P 500 over the long term. You may vote once every thirty days.
